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Abstract
Aicardi–Goutières syndrome (AGS) provides a monogenic model of
nucleic acid-mediated inflammation relevant to the pathogenesis
of systemic autoimmunity. Mutations that impair ribonuclease
(RNase) H2 enzyme function are the most frequent cause of this
autoinflammatory disorder of childhood and are also associated
with systemic lupus erythematosus. Reduced processing of either
RNA:DNA hybrid or genome-embedded ribonucleotide substrates is
thought to lead to activation of a yet undefined nucleic acid-
sensing pathway. Here, we establish Rnaseh2bA174T/A174T knock-in
mice as a subclinical model of disease, identifying significant inter-
feron-stimulated gene (ISG) transcript upregulation that recapitu-
lates the ISG signature seen in AGS patients. The inflammatory
response is dependent on the nucleic acid sensor cyclic GMP-AMP
synthase (cGAS) and its adaptor STING and is associated with
reduced cellular ribonucleotide excision repair activity and
increased DNA damage. This suggests that cGAS/STING is a key
nucleic acid-sensing pathway relevant to AGS, providing additional
insight into disease pathogenesis relevant to the development of
therapeutics for this childhood-onset interferonopathy and adult
systemic autoimmune disorders.
Keywords Aicardi–Goutières syndrome; autoinflammation; cGAS-STING;
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Introduction
Nucleic acid sensing is a key element of antimicrobial immunity
(Wu & Chen, 2014). Diverse nucleic acid sensors act as pattern
recognition receptors (PRRs), initiating innate immune responses
necessary to protect against pathogens containing a diverse range of
nucleic acid species (Wu & Chen, 2014). Such innate immune acti-
vation, arising from sensing of cellular nucleic acids, is also impli-
cated in autoimmune disease, most notably systemic lupus
erythematosus (SLE) (Wahren-Herlenius & Dorner, 2013).
The autoinflammatory disorder Aicardi–Goutie`res syndrome
(AGS) has provided important insights into mechanisms under-
lying nucleic acid-mediated inflammation (Crow & Manel, 2015).
AGS typically presents in infancy following a period of normal
development, with sterile pyrexia, irritability, seizures and loss of
developmental milestones (Crow & Livingston, 2008). Persisting
severe physical and intellectual disability is frequent, and extra-
neurological features can include vasculitic skin lesions (Crow &
Livingston, 2008; Crow et al, 2015). Increased type 1 interferon
activity is most reliably detected during the early stages of the
disease (Crow et al, 2015). However, upregulated interferon-
stimulated gene (ISG) transcripts in blood have proven to be the
most robust diagnostic biomarker in AGS patients, and an “ISG
signature” often persists long after the initial stages of disease (Rice
et al, 2013; Crow et al, 2015).
Although AGS is a monogenic disorder, it is genetically heteroge-
neous, with seven genes implicated to date, encoding several
nucleic acid processing enzymes and a cytosolic nucleic acid sensor.
These comprise the RNASEH2A, RNASEH2B and RNASEH2C
proteins of the RNase H2 endonuclease complex (Crow et al, 2006b)
as well as TREX1, SAMHD1, ADAR and IFIH1 (Crow et al, 2006a;
Rice et al, 2009, 2012, 2014). Heterozygous mutations in the three
RNase H2 genes (Gu¨nther et al, 2015) and TREX1 (Lee-Kirsch et al,
2007) are also associated with systemic lupus erythematosus.
Partial loss-of-function biallelic mutations in the RNase H2 genes
are the major cause of AGS, accounting for over half of all cases
(Crow et al, 2015). RNase H2 is ubiquitously expressed and func-
tions alongside RNase H1 to degrade cellular RNA:DNA hetero-
duplexes. Although the exact in vivo substrates of these nucleases
remain to be identified, they are thought to act on RNA:DNA
hybrids such as those arising during nuclear DNA replication and
R-loop formation (Cerritelli & Crouch, 2009). Unlike RNase H1, RNase
H2 also cleaves and initiates the removal of single ribonucleotides
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embedded in DNA (Eder et al, 1993; Rydberg & Game, 2002), a
process known as ribonucleotide excision repair (RER) (Sparks et al,
2012). RNase H2 is essential for mammalian genome stability, with
complete loss of RNase H2 resulting in embryonic lethality (Reijns
et al, 2012; Hiller et al, 2012).
Intracellular accumulation of aberrant nucleic acid species is
believed to trigger intrinsic nucleic acid sensors initiating auto-
immunity in AGS (Crow & Manel, 2015). Trex1/ and Adar1/
mouse models have, respectively, implicated the cGAS-STING
(Ablasser et al, 2014; Ahn et al, 2014a; Gray et al, 2015; Gao et al,
2015) and MDA5/IFIH1 (Liddicoat et al, 2015) pathways in driving
immune activation. However, to date, an immune phenotype in
mice has not been described for mutations in any of the RNase H2
genes. It therefore remains to be determined whether a similar
pathophysiological mechanism underlies RNase H2 deficiency, and
consequently, the nature of the activated immune pathway in the
majority of AGS patients is yet to be defined.
Here, we identify a sub-clinical phenotype of ISG induction in a
mouse model of the RNASEH2B-A177T mutation, the single most
common missense mutation found in AGS patients. We demonstrate
that this is dependent on the cGAS/STING pathway, consistent with
PRR sensing of cell-intrinsic nucleic acids in RNase H2-deficient
cells.
Results
A hypomorphic RNase H2 mouse model for Aicardi–
Goutières syndrome
A mouse model was created by targeted knock-in of the A174T
missense mutation (c.520G>A) into exon 7 of Rnaseh2b in mouse
embryonic stem cells using homologous recombination (Fig 1A–D
and Appendix Fig S1). A C57BL/6J congenic Rnaseh2bA174T/A174T
mouse line was established using these cells, orthologous to the
most common pathogenic mutation identified in patients with AGS,
RNASEH2B-A177T. This mutation resulted in reduced cellular levels
of all three RNase H2 subunits in Rnaseh2bA174T/A174T mouse
embryonic fibroblasts (MEFs) and RNASEH2BA177T/A177T AGS
patient lymphoblastoid cells (LCLs) (Fig 1E). This is consistent with
reduced RNase H2 complex stability predicted from structural and
biochemical studies that showed that the RNASEH2B-RNASEH2C
interaction interface is disrupted by the A177T substitution (Figiel
et al, 2011; Reijns et al, 2011). Cellular RNase H2 activity was also
significantly reduced to 30  2% activity in Rnaseh2bA174T/A174T
MEFs (Fig 1F and G) and 49  3% activity in RNASEH2BA177T/A177T
LCLs (Fig 1H), assessed against an embedded ribonucleotide
substrate. More pronounced reduction in the mouse cells may be
explained by the presence of a neomycin selection cassette between
exon 6 and 7, causing reduced Rnaseh2b transcript levels (~60% of
wild type; data not shown).
Despite marked impairment of RNase H2 activity, Rnase-
h2bA174T/A174T mice had no overt phenotype and remained healthy
when aged. Full pathological examination of brain, liver, heart,
lungs, thymus, spleen, gastrointestinal tract, kidneys, skin and
tongue from mice (n = 9) did not detect histological features of
inflammation, infection or neoplasia at 1 year (data not shown). In
particular, there was no evidence of intracranial calcification,
leukodystrophy, chilblain vasculitis or cardiomyopathy, clinical
features associated with AGS in humans (Crow et al, 2015).
Notably, histopathological signs of inflammation are also not
evident in Samhd1/ mice, although activation of innate immune
signalling does occur, with ISG upregulation evident (Behrendt et al,
2013; Rehwinkel et al, 2013). We therefore investigated whether
this was also the case in Rnaseh2bA174T/A174T mice.
ISG upregulation is present in tissues from
Rnaseh2bA174T/A174T mice
Since an ISG transcriptional response is the most robust biomarker
of inflammation in human patients (Rice et al, 2013), we performed
RT–qPCR for a panel of AGS-relevant ISGs on RNA extracted from
adult Rnaseh2bA174T/A174T mouse tissues. A broad upregulation of
ISGs was detected in heart (Fig 2A) along with significant induction
of a subset of ISGs in the kidney (Fig 2B), but without any ISG
response evident in brain (Fig 2C). The twofold to fourfold induc-
tion of ISGs we observed in Rnaseh2bA174T/A174T heart tissue is
comparable to the fourfold to sevenfold induction seen in Samhd1/
mouse tissue (Rehwinkel et al, 2013). While an overt inflammatory
phenotype is seen in Trex1/ mice (Morita et al, 2004; Gall et al,
2012), pathological signs of neuroinflammation are not evident,
although ISG upregulation in brain tissue can be detected (Pereira-
Lopes et al, 2013). Given that the autoinflammatory process
appears to initiate in the Trex1/ heart (Gall et al, 2012), there
are similarities between the pattern of inflammation in Trex1/
mice and the ISG tissue expression pattern in Rnaseh2bA174T/A174T
mice.
A proinflammatory response in Rnaseh2b/ MEFs
We next investigated whether the observed ISG induction was
directly attributable to reduced RNase H2 activity. To address this,
we examined cells from a second independent mouse line carrying a
null allele of Rnaseh2b (Rnaseh2btm1d), derived from the EUCOMM
knockout-first Rnaseh2btm1a allele, from which exon 5 of Rnaseh2b
had been excised by Cre recombinase. Given the early embryonic
lethality of Rnaseh2b/ mice (Reijns et al, 2012), mouse embryonic
fibroblasts (MEFs) were generated on a p53/ background. Here-
after, we will refer to the resulting Rnaseh2b/ p53/ and Rnase-
h2b+/+ p53/ cells simply as Rnaseh2b/ and Rnaseh2b+/+,
respectively. Loss of RNase H2 activity in Rnaseh2b/ cells was
confirmed (Fig 3A).
Significant upregulation of ISG transcripts was again apparent,
on comparing six independent Rnaseh2b/ MEF lines with four
Rnaseh2b+/+ control MEF lines (Fig 3B and Appendix Fig S2A). To
further characterise the nature of the response, two of the Rnase-
h2b/ MEF lines with stronger ISG upregulation were compared to
control lines by gene expression microarray (Fig 3C and
Appendix Table S1). Of the 29 upregulated genes achieving genome-
wide significance, 17 were documented ISGs and activation of non-
ISG immune response pathways was not evident. In particular, there
was significant induction of two ISG genes encoding proinflamma-
tory cytokines: Ccl5 (P = 0.0067) and Cxcl10 (P = 0.039). Upregula-
tion of both transcripts was confirmed by RT–qPCR, and ELISA of
culture supernatants from all six Rnaseh2b/ lines demonstrated
significantly increased CCL5 and CXCL10 secretion (Fig 3D and E,
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Figure 1. RNase H2 complex levels and enzymatic activity are reduced in Rnaseh2bA174T/A174T mouse and RNASEH2BA177T/A177T AGS patient cells.
A Targeted mutagenesis of the Rnaseh2b gene. Top: A 7-kb region of the Rnaseh2b genomic locus; black boxes, exons 6 (ex6) and 7 (ex7). Middle: NotI/SalI restriction
fragment of the targeting construct, comprising 4.5 kb of genomic DNA and a neomycin selection cassette (Neo) flanked by loxP sites (triangles). (Bottom) Targeted
locus containing exon 7 with the c.520G>A mutation (ex7*). Red arrowheads, primers used to confirm correct targeting. Red bar, 400-bp probe for Southern
blotting.
B Southern blotting confirms successful targeting. Introduction of an additional EcoRI site results in a 4.1-kb restriction fragment detectable by Southern for targeted
ES cells (A174T/+) but not for parental DNA (+/+).
C Capillary sequencing for Rnaseh2b+/+, Rnaseh2bA174T/+ and Rnaseh2bA174T/A174T DNA confirmed the presence of the introduced missense mutation.
D Mouse genotyping by multiplex PCR. Top: A 221-bp PCR product is present in wild-type mice (+/+); the Rnaseh2bA174T allele (also) gives a 460-bp product. Bottom:
Position of forward (x) and reverse primers (y, z).
E Immunoblotting demonstrates depletion of all three RNase H2 protein subunits in Rnaseh2bA174T/A174T MEFs and RNASEH2BA177T/A177T LCLs. Representative of three
independent experiments.
F Schematic showing enzyme activities attributed to RNase H1 and RNase H2 (DNA blue, RNA red).
G, H RNase H2 enzyme activity is reduced in mouse and patient cells. (G) Enzyme activity for Rnaseh2bA174T/A174T MEFs and passage-matched Rnaseh2b+/+ controls,
against RNase H substrate (RNA:DNA heteroduplex) and RNase H2-specific substrate, double-stranded DNA with a single-embedded ribonucleotide (DRD:DNA).
Mean activity for three independent cell lines, error bars represent SEM. Enzymatic activity expressed relative to the average value of control MEFs. ***P < 0.001,
two-tailed t-test (n = 3 Rnaseh2bA174T/A174T and n = 3 Rnaseh2b+/+ control MEF lines). (H) RNase H2 activity in LCLs from two independent healthy controls and an
AGS patient homozygous for the RNASEH2B-A177T mutation. Enzyme activity normalised to average activity of control lines. Three independent experiments, error
bars represent SEM. ***P < 0.001 versus either control, two-tailed t-test.
Source data are available online for this figure.
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and Appendix Fig S2B). Notably, these cytokines have previously
been implicated in AGS neuroinflammation in humans (van Heteren
et al, 2008; Takanohashi et al, 2013; Cuadrado et al, 2015). We
therefore concluded that impaired RNase H2 activity in vitro and
in vivo results in a similar inflammatory response to that observed
in patients with AGS, and like for Trex1 deficiency (Gall et al, 2012)
is present in non-immune cells.
ISG activation is dependent on the cGAS-STING nucleic acid-
sensing pathway
We next sought to determine the nucleic acid-sensing pathway
responsible for ISG induction in Rnaseh2b/ cells. Three
pathways have recently been implicated in the sensing of RNA:
DNA hybrids: TLR9 (Rigby et al, 2014), cGAS-STING (Mankan
et al, 2014) and the NLRP3 inflammasome (Kailasan Vanaja et al,
2014). We therefore postulated that one of these nucleic acid
sensors would be responsible for the ISG signature, given that
RNase H2 is the major enzyme degrading RNA:DNA hybrids in
mammalian cells (Büsen, 1980; Reijns et al, 2012). However, as
IL-1b and IL-18 were both undetectable in culture supernatants
from Rnaseh2b/ cells (data not shown), an inflammasome-
mediated response was unlikely. While the observed ISG induc-
tion would be consistent with TLR9 activation, signalling is
impaired by deficient proteolytic processing of the receptor in
MEFs (Ewald et al, 2008), and we therefore prioritised assessment
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Figure 2. Increased ISG expression in tissues from Rnaseh2bA174T/A174T mice.
A Transcript levels of multiple ISGs are significantly elevated in heart.
B Transcript levels of a subset of ISGs are significantly increased in kidney.
C No ISG upregulation is evident in the brain.
Data information: ISG transcript levels determined by RT–qPCR normalised to transcript levels of the housekeeping gene HPRT (Oas1a was undetectable in brain). Each
data point represents the mean of technical replicates of tissue RNA from a single mouse. n = 9 nine-month-old Rnaseh2bA174T/A174T mice and n = 4 age-matched
control wild-type C57BL/6J mice. Horizontal line, mean; error bars, SEM. *P < 0.05, **P < 0.01, two-tailed t-test.
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of the cGAS-STING pathway. We performed siRNA depletion of
cGAS in Rnaseh2b/ MEFs and found that cGAS depletion signifi-
cantly abrogated the ISG response and CCL5 production (Fig 4A).
siRNA depletion of STING, the adaptor associated with cGAS sens-
ing, also significantly reduced ISG induction and CCL5 secretion
(Fig 4A), implicating the cGAS/STING-sensing pathway in innate
immune activation in Rnaseh2b/ cells. The siRNA knock-down
was specific to cGAS and STING, respectively (Fig 4A), and cells
remained fully responsive to poly(I:C) (Appendix Fig S3).
To substantiate that cGAS is required for ISG induction, CRISPR/
Cas9 genome editing was performed to knock out the cGAS gene in
Rnaseh2b/ MEFs. Rnaseh2b/ MEF clones in which cGAS dele-
tion had not occurred were also identified, to act as experimental
controls. While ISG transcript upregulation and cytokine production
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Figure 3. A proinflammatory response is detectable in vitro in Rnaseh2b/ MEFs.
Rnaseh2b/ MEFs have significantly elevated ISG transcript levels and secrete the proinflammatory cytokines CXCL10 and CCL5.
A Validation of Rnaseh2b/ MEF lines. RER activity (DRD:DNA) is undetectable in a Rnaseh2b/ line consistent with complete inactivation of the Rnaseh2b gene
(Reijns et al, 2012). Mean of three independent experiments; error bars, SEM, ****P < 0.0001, two-tailed t-test. Rnaseh2b/ and Rnaseh2b+/+ control MEFs on a
C57BL/6 p53/ background.
B ISG transcript levels are increased in Rnaseh2b/ MEFs.
C BeadArray transcript analysis (Illumina) detected induction of multiple ISGs, including the cytokines CXCL10 and CCL5, but not other cytokine transcripts in
Rnaseh2b/ MEFs. Plotted, average fold enrichment versus P-value of significantly upregulated transcripts (P < 0.05, after multiple testing correction) comparing two
Rnaseh2b/ MEF lines versus 4 Rnaseh2b+/+ MEF lines. Seventeen out of 29 transcripts are ISGs.
D Cxcl10 and Ccl5 transcripts (detected by RT–qPCR) are significantly elevated.
E Increased CXCL10 and CCL5 protein (detected by ELISA) is secreted by Rnaseh2b/ MEFs.
Data information: Data in (B, D, E) are mean from three experiments for six independent Rnaseh2b/ MEF lines versus four independent Rnaseh2b+/+ MEF lines. Error
bars, SEM. *P < 0.05, **P < 0.01, Mann–Whitney U-test.
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(CCL5 and CXCL10) were still observed in such control cells, both
were abrogated in CRISPR/Cas9 targeted Rnaseh2b/ cGas/ cells
(Fig 4B–D), establishing that the innate immune activation found in
Rnaseh2b/ MEFs is dependent on cGAS.
To determine whether ISG induction was dependent on the
cGAS-STING-sensing pathway in vivo, we intercrossed Rnase-
h2bA174T/A174T and Sting/ mice. We found that ISG transcript
levels from Rnaseh2bA174T/A174T Sting/ heart tissue were signifi-
cantly reduced compared to Rnaseh2bA174T/A174T Sting+/+ controls
(Fig 4E), while no significant reduction was observed when compar-
ing Rnaseh2b+/+ Sting/ and Rnaseh2b+/+ Sting+/+ controls
(Fig 4F). Hence, a STING-dependent ISG response also occurs
in vivo in Rnaseh2bA174T/A174T mice, implicating the cGAS-STING
pathway in the ISG induction observed in RNase H2 AGS patients.
Loss of RNase H2-specific activity results in ISG induction
Finally, the fact that both dsDNA (Sun et al, 2013; Gao et al, 2013)
and RNA:DNA hybrids (Mankan et al, 2014) can bind and activate
the cytoplasmic nucleic acid sensor cGAS prompted us to consider
the origin of the cGAS ligand present in RNase H2-deficient cells.
Abrogated RNase H2 function could give rise to cytosolic accumula-
tion of RNA:DNA heteroduplexes as a consequence of reduced RNA:
DNA degradation of structures such as R-loops or active retro-
elements/endogenous retroviruses (Chon et al, 2013; Rigby et al,
2014; Moelling & Broecker, 2015). Alternatively, cytoplasmic DNA
with embedded ribonucleotides may accumulate as a consequence
of impaired RER that resulted in genome instability (Reijns et al,
2012; Hiller et al, 2012). To address these possibilities, we
performed complementation experiments in RNase H2 null cells, to
establish which enzymatic activity was associated with the pro-
inflammatory response.
Rnaseh2b/ cells were complemented by retroviral transduction
of either Rnaseh1 or Rnaseh2b, respectively, to reconstitute cellular
RNase H activity or RNase H plus RER activity. Overexpression of
RNase H1 in Rnaseh2b/ cells restored cellular enzyme activity
against RNA:DNA hybrids to 81  10% of the level seen in Rnase-
h2b+/+ cells (Fig 5A), but did not alleviate DNA damage (Fig 5B
and C). Complementation with Rnaseh2b reconstituted activity
against both types of substrates (Fig 5A) and also returned DNA
damage to levels seen in Rnaseh2b+/+ cells (Fig 5B and C). Recon-
stitution with Rnaseh2b was able to reduce cytokine and ISG
responses close to wild-type levels (Fig 5D–F), while Rnaseh1
complementation did not (Fig 5D–F). While some reduction was
seen in CXCL10, ISG expression in Rnaseh1 complemented cells was
otherwise the same, if not greater than, in parental Rnaseh2b/
cells. cGAS-dependent ISG induction in Rnaseh2b/ cells is there-
fore associated with DNA damage and loss of RNase H2-specific
activity, rather than an overall reduction in cellular activity against
RNA:DNA hybrids.
Discussion
Here, we establish that RNase H2 deficiency leads to a proinflamma-
tory response which is dependent upon the cGAS/STING pathway.
The resulting ISG transcriptional response and induction of pro-
inflammatory cytokines are consistent with cell-intrinsic innate
immune activation. ISG activation varied between tissues, which
may explain why such transcriptional changes were not reported
◀ Figure 4. ISG induction in RNase H2 deficiency is dependent on the cGAS-STING nucleic acid-sensing pathway.A ISG activation and cytokine secretion in Rnaseh2b/ MEFs is markedly impaired by cGAS or STING siRNA depletion. Upper left and lower panels: RT–qPCR of Ifit1,
cGas and Sting transcripts, 48 h after siRNA targeting luciferase (control), cGAS or STING. Upper right panel: CCL5 is significantly reduced in culture supernatants
48 h after cGAS or STING depletion. Concentration of CCL5 (ELISA), normalised to luciferase siRNA control levels in each experiment. Mean from three independent
experiments using one Rnaseh2b/ MEF line; error bars, SEM. *P < 0.05, **P < 0.01, two-tailed t-test for RT–qPCR, one-sample t-test for CCL5 ELISA.
B–D ISG induction and cytokine secretion is abolished in Rnaseh2b/ cGas/ MEFs. cGas was targeted by CRISPR/Cas9 genome editing of a Rnaseh2b/ MEF line to
inactivate cGAS/STING signalling. In addition to sequence validation, functional inactivation of cGAS was confirmed in Rnaseh2b/ cGas/ CRISPR lines by the
absence of CCL5 secretion in response to dsDNA (Appendix Fig S4). CCL5 (B) and CXCL10 (C) production, as well as ISG expression (D), was abrogated in
Rnaseh2b/ cGas/ clones, assessed by ELISA and RT–qPCR, respectively. Four independent experiments, n = 2 Rnaseh2b/ cGas/ clones, n = 4 Rnaseh2b/
cGas+/+ clones, error bars, SEM of each experiment; *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed t-test.
E ISG induction in Rnaseh2bA174T/A174T mice is STING dependent. RT–qPCR of RNA extracted from hearts from Sting+/+ Rnaseh2bA174T/A174T (n = 4) and
Sting/Rnaseh2bA174T/A174T (n = 6) 3-month-old mice. Each data point represents the mean of technical triplicates from one mouse. Horizontal line, mean; error
bars, SEM. *P < 0.05, Mann–Whitney U-test.
F Absence of STING does not significantly decrease basal ISG expression. RT–qPCR of RNA extracted from hearts from Sting+/+ (n = 3) and Sting/ (n = 5) three-
month-old mice. Each data point represents the mean of technical triplicates from one mouse. Horizontal line, mean; error bars, SEM. *P < 0.05, Mann–Whitney
U-test.
Figure 5. Cellular RER and not enzyme activity against RNA:DNA hybrids correlates with DNA damage and proinflammatory response.
A Overexpression of RNase H1 in Rnaseh2b/ cells restores RNase H activity against RNA:DNA hybrids to 81  10% of wild-type levels, while overexpression of
RNASEH2B restores cellular enzyme activity for cleavage of both RNA:DNA and DRD:DNA substrates (RER). Rnaseh2b/ MEFs were complemented with Rnaseh1
(+H1), Rnaseh2b (+H2B) or EGFP by retroviral infection. Mean of n = 3 independent experiments  SEM.
B, C DNA damage is reduced to wild-type levels by complementation with Rnaseh2b but not Rnaseh1, measured by 53BP1 foci formation in detergent-extracted fixed
cells. (B) Representative images (scale bar, 10 lm). (C) At least 150 cells were counted for each cell line in three independent experiments. Mean  SEM,
****P < 0.0001 two-tailed t-test.
D–F CCL5 (D) and CXCL10 production (E), as well as ISG induction (F) in Rnaseh2b/ MEFs are reduced close to wild-type levels (Rnaseh2b+/+), by complementation
with Rnaseh2b but not Rnaseh1. Mean of n = 6 independent experiments  SEM for complemented cells; n = 3 independent experiments for Rnaseh2b/ parental
and Rnaseh2b+/+ controls cells. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 two-tailed t-test indicates significantly reduced expression compared to
Rnaseh2b/ parental cells.
▸
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previously in Rnaseh2b/ or Rnaseh2btm1a/tm1a embryos (Reijns
et al, 2012; Hiller et al, 2012). The precise factors determining
tissue-specific cGAS activation are currently unclear, but could
include the sensitivity of the cGAS/STING pathway in particular cell
types, their level of cell proliferation, the rate of accumulation of
immunogenic nucleic acids and the counteracting influences of
cellular processes degrading such nucleic acids.
Despite tissue-specific ISG upregulation, Rnaseh2bA174T/A174T
mice have a subclinical phenotype without any overt inflammatory
pathology, and so, like all other AGS mouse models do not recapit-
ulate the neuroinflammation seen in human AGS patients (Rabe,
2013; Behrendt & Roers, 2014). It will therefore be important to
confirm that the innate immune pathways implicated in Trex1,
Adar1 and now RNase H2 deficiency, through the use of mouse
models, are also relevant to the human autoinflammatory pheno-
type in AGS patients in whom these genes are affected. Samhd1/
mice, like Rnaseh2bA174T/A174T mice, display an ISG response in
the absence of detectable pathology (Behrendt et al, 2013;
Rehwinkel et al, 2013). In contrast a strong ISG response in Adar1
null or editing-deficient mice is associated with embryonic lethality
(Mannion et al, 2014; Liddicoat et al, 2015; Pestal et al, 2015),
and with autoinflammatory cardiomyopathy and multi-tissue
involvement in Trex1/ mice (Morita et al, 2004; Stetson et al,
2008; Gall et al, 2012). The variation in severity between different
AGS gene mouse models remains unexplained, although it may be
meaningful that mutations in human RNASEH2B are associated
with the least severe disease course, with AGS onset generally in
infancy, in contrast to the prenatal/neonatal onset more commonly
seen in TREX1 patients (Crow et al, 2015). Also, additional trig-
gers, such as viral infection, have been proposed to be relevant to
the pathogenesis of AGS (Crow & Manel, 2015). Reports of marked
phenotypic variability in sibling pairs with identical RNASEH2B or
RNASEH2C mutations (Vogt et al, 2013; Tu¨ngler et al, 2014) are
consistent with the possibility of such environmental factors
impacting on disease severity. The Rnaseh2bA174T/A174T mouse and
other models provide an opportunity for future investigation of
these aspects.
Identification of the precise source of the immunogenic nucleic
acids responsible for the inflammatory phenotype remains central to
providing further mechanistic insight. Dependence of the ISG
response in RNase H2- and Trex1-deficient mouse cells on the
cGAS/STING pathway suggests that accumulation of cytoplasmic
DNA is common to both TREX1 and RNase H2 AGS, given that DNA
is the canonical ligand for cGAS (Sun et al, 2013; Gao et al, 2013).
Our complementation experiments would favour this possibility, as
normalising cellular enzymatic activity against RNA:DNA hybrids
does not rescue the proinflammatory response. However, immuno-
genic RNA:DNA hybrids cannot be completely excluded, given that
some hybrids might be specifically degraded by the RNase H2
enzyme (Chon et al, 2013), although the mechanism for such dif-
ferential substrate specificity for RNase H1 and H2 enzymes is
currently unclear.
So far, we have been unable to ascertain whether cytoplasmic
double-stranded nucleic acids accumulate in RNase H2-deficient
cells. However, given that impaired RER causes reduced genome
stability, DNA fragments resulting from DNA strand breaks are a
potential origin of immunogenic cytoplasmic DNA (Ahn et al,
2014b; Hartlova et al, 2015; Shen et al, 2015), while an alternative
source could be reverse-transcribed retroelements, which are
known to be activated upon DNA damage (Farkash & Luning Prak,
2006). Irrespective of the chemical nature of the ligand, our obser-
vation that cGAS plays a central role in the ISG response in RNase
H2 deficiency provides further impetus for defining the source of
the immunogenic nucleic acids. While cytoplasmic DNA was first
detected in 2007 in Trex1/ cells, even here the precise origin still
remains elusive, with conflicting evidence supporting either
endogenous retroviruses/retroelements (Stetson et al, 2008) or
genome instability (Yang et al, 2007). Purification of the responsi-
ble immunostimulatory nucleic acids could provide the solution;
however, the specific isolation of such low-abundant cytoplasmic
nucleic acids remains a formidable technical challenge. This has
precluded a definitive answer to date, but may be aided by impli-
cating cGAS as the nucleic acid sensor binding immunogenic
nucleic acids in both Trex1- and RNase H2-deficient cells, inform-
ing potential future biochemical strategies.
In summary, our findings implicate the cGAS-STING pathway in
RNase H2 AGS and, together with the previously attributed role in
Trex1 deficiency, suggest it is the most common signalling pathway
driving inflammation in AGS, relevant also to the pathogenesis of
SLE (Lee-Kirsch et al, 2007; Gu¨nther et al, 2015). Targeting this
pathway therefore represents a relevant therapeutic strategy for the
treatment of this childhood interferonopathy and related adult-onset
autoimmune conditions.
Materials and Methods
Generation of Rnaseh2b-A174T ES cells
Gap repair was used to retrieve a genomic fragment of 4.5 kb
from BAC bMQ454F14 (Source Bioscience Lifesciences), which
included exon 6 and 7 of the mouse Rnaseh2b locus (nucleotides
62977197-62981727 of Chr14, Ensembl release 64). Subsequent
bacterial recombination was used to insert a neomycin cassette
flanked by loxP sites between exon 6 and 7, generating a target-
ing vector with two external homology arms of 2.8 kb and
1.7 kb. A point mutation c.520G>A (A174T) was inserted into
exon 7 of mouse Rnaseh2b by site-directed-mutagenesis (Quik-
change, Agilent Technologies). After linearisation and vector back-
bone removal by digestion with NotI and SalI, and electroelution/
purification by Elutrap, the targeting cassette was electroporated
into 129/Ola E14Tg2AIV embryonic stem cells. Southern blotting
and long-range PCR were used to identify correctly targeted
clones. Capillary sequencing was performed to ensure the pres-
ence of the c.520G>A mutation and absence of other coding
changes. The ES cell clone was karyotyped before injection into
C57BL/6J mouse blastocysts.
Mice
Rnaseh2bA174T
Male chimeras resulting from blastocyst injection with Rnase-
h2bA174T/+ ES cells were crossed to C57BL/6J females, giving rise
to heterozygous Rnaseh2b knock-in mice carrying the A174T muta-
tion (Rnaseh2btm2-hgu-A174T, elsewhere referred to as Rnase-
h2bA174T). These were backcrossed to F11 on the C57BL/6J
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background to establish congenicity and subsequently maintained
as a homozygous mutant line. C57Bl/6J control mice were bought
in at 4–6 weeks of age from the same source as those used in
backcrossing, to ensure genetic matching to a level of > 99.97%
identity. All mice were housed in the same facility in the same
room in conventional cages and fed the same water and food until
they were analysed. Murine data were analysed unblinded to geno-
type. Sample sizes of 3–7 mice per group were similar to previous
studies.
Rnaseh2btm1d
Knockout-first Rnaseh2b mice were generated by blastocyst injec-
tion of the Rnaseh2btm1a(EUCOMM)Wtsi C57BL/6N ES cell clone
EPD0087_4_A02 (EUCOMM ID: 24441) and crossing of male
chimeras to C57BL/6J females. The Rnaseh2btm1d allele, in which
exon 5 is deleted, was generated by crossing of Rnaseh2btm1a/+
mice to mice with ubiquitous expression of FLPe recombinase to
delete the genetrap cassette. Rnaseh2btm1c/+ offspring were
subsequently crossed to Cre745 mice (a kind gift from DJ Klein-
jan, University of Edinburgh), containing a CAGGS-Cre construct
in which Cre recombinase is under control of a chicken b-actin
promoter (Araki et al, 1995; Kleinjan et al, 2006) to excise
Rnaseh2b exon 5. The resulting Rnaseh2btm1d/+ (Rnaseh2b+/)
mice were maintained on the C57BL/6J background. The pheno-
type of Rnaseh2btm1d/tm1d embryos was indistinguishable from
that previously described for Rnaseh2bE202X/E202X embryos (Reijns
et al, 2012).
Other strains
Trp53tm1Tyj/J mice on the C57BL/6J background have been
described previously (Jacks et al, 1994) and were kindly provided
by Andrew Wood, University of Edinburgh. Interbreeding with
Rnasehbtm1d/+ mice was used to generate Rnaseh2b+/+ p53/ and
Rnaseh2b/ p53/ MEFs.
Sting/Mpys/ mice on the C57BL/6 background have been
described previously (Jin et al, 2011) and were kindly provided by
Jan Rehwinkel, University of Oxford, with the consent of John
Cambier, University of Colorado SOM and National Jewish Health.
Interbreeding with Rnaseh2bA174T/A174T mice generated Rnase-
h2bA174T/A174T Sting/ mice.
Mb21d1/cGas/ MEFs derived from C57BL/6NTac-Mb21d1tm1a
(EUCOMM)Hmgu/IcsOrl mice were a kind gift from Jan Rehwinkel,
Oxford University. These mice were originally obtained from the
Institute Clinique de la Souris through the European Mouse Mutant
Archive.
All mouse studies were conducted according to UK Home Office
regulations under a UK Home Office project licence.
Genotyping
DNA was extracted from earclips (boiled in 50 ll 25 mM NaOH,
0.2 mM EDTA for 30 min at 95°C, cooled and then neutralised with
50 ll 40 mM Tris base) or embryos (tail tips treated with DirectPCR
Lysis Reagent (Viagen) according to the manufacturer’s instruc-
tions). All genotyping PCRs were performed using a multiplex
three-primer strategy and Taq ReddyMix PCR Master Mix (Thermo
Scientific), as previously described for Rnaseh2bE202X/E202X (Reijns
et al, 2012) and p53/ (Jacks et al, 1994). For Rnaseh2btm1d/+,
Sting/Mpys+/ as well as all other primers and product sizes, see
Appendix Table S2.
Generation of murine embryonic fibroblast lines and assessment
of innate immune activation
Independent Rnaseh2bA174T/A174T and Rnaseh2b+/+ MEF lines were
generated from individual E13.5 embryos. After removing the head
and internal organs, the embryos were mechanically dissociated in
growth medium (DMEM, 10% FCS, 50 U/ml penicillin and 50 lg/ml
streptomycin, 0.1 mM b-mercaptoethanol). Resulting suspensions
were grown at 37°C, 5% CO2 and 3% O2, and non-adherent cells
removed after 24 h. MEFs were subsequently maintained and
passaged under the same conditions. Independent Rnaseh2b/
p53/ and Rnaseh2b+/+ p53/ MEF lines were similarly gener-
ated from individual whole E10.5 embryos. For assessment of ISG
upregulation and cytokine production, MEFs were plated at
2 × 105 cells per well in 12-well plates. The following day culture
medium was replaced with 800 ll of fresh medium. After a further
20 h, the culture medium was removed for assessment by ELISA to
determine CXCL10 and CCL5 concentrations (R&D Systems). RNA
was extracted from adherent cells using the RNeasy kit (Qiagen) as
per manufacturer’s instructions and included DNase I treatment.
Extracted RNA was stored at 80°C until analysis.
AGS patient cells
A lymphoblastoid cell line from an AGS patient with the RNASEH2B-
A177T mutation (kindly donated by Professor Yanick Crow, Univer-
sity of Manchester) and non-affected controls were generated from
peripheral blood samples by EBV transformation using standard
methods. Lymphoblastoid cell lines (LCLs) were maintained in RPMI
1640 supplemented with 15% foetal bovine serum, L-glutamine,
50 U/ml penicillin and 50 lg/ml streptomycin at 37°C, 5% CO2 and
normoxic conditions. The A177T/A177T mutation in the patient cell
line was validated using Sanger sequencing.
Immunoblotting
Whole-cell lysates were prepared by lysing cells in 50 mM Tris (pH 8),
280 mM NaCl, 0.5% NP-40, 0.2 mM EDTA, 0.2 mM EGTA, 10%
glycerol (vol/vol), 1 mM DTT and 1 mM PMSF for 10 min at 4°C.
Lysed cells were then diluted 1:1 with 20 mM HEPES (pH 7.9),
10 mM KCl, 1 mM EDTA, 10% glycerol (vol/vol), 1 mM DTT and
1 mM PMSF for an additional 10 min, and extracts were cleared by
centrifugation (17,000 g, 5 min, 4°C). Equal amounts of proteins
from supernatants (concentrations determined using the Bradford
method) were separated by SDS–PAGE on NuPAGE Novex Bis-Tris
4–12% protein gels (Thermo Fisher Scientific) and transferred to
PVDF membrane. Membranes were blocked in 5% milk in TBS with
0.2% Tween and probed with antibodies raised against mouse or
human recombinant RNase H2, as previously described (Reijns et al,
2012), RNASEH2A (TA306706, Origene) or actin (A2066, Sigma).
RNase H enzyme assays
Enzyme activity assays were performed using a FRET-based
fluorescent substrate release assay, as previously described
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(Reijns et al, 2011). Briefly, 10 mM of fluorescein-labelled
oligonucleotides (GATCTGAGCCTGGGaGCT for RNase H2 specific
activity, DRD:DNA, or gaucugagccugggagcu for total RNase H activ-
ity, RNA:DNA; upper case DNA, lower case RNA) was annealed to a
complementary DABCYL-labelled DNA oligonucleotide (Eurogentec)
in 60 mM KCl, 50 mM Tris–HCl pH 8. Activity against double-
stranded DNA substrate of the same sequence was measured and
used to correct for non-RNase H2 activity against DRD:DNA
substrate. Reactions were performed in 100 ll of buffer (60 mM
KCl, 50 mM Tris–HCl pH 8, 10 mM MgCl2, 0.01% BSA, 0.01%
Triton X-100) with 250 nM substrate in 96-well flat-bottomed plates
at 24  2°C. Whole-cell lysates were prepared as described above,
and the final protein concentration used per reaction was 100 ng/ll
(for DRD:DNA substrate), 50 ng/ll (for RNA:DNA substrate) for
MEFs, and 32 or 16 ng/ll, respectively, for LCLs. Fluorescence was
read for 100 ms using a VICTOR2 1420 multilabel counter (Perkin
Elmer), with a 480-nm excitation filter and a 535-nm emission filter.
RT–qPCR
Murine tissues were snap-frozen in liquid nitrogen and stored at
80°C until RNA extraction via homogenisation and using the
RNeasy kit (Qiagen) as per manufacturer’s instructions. cDNA was
prepared from RNA from murine tissues or MEFs using AMV RT
(Roche) and random oligomer primers (Thermo Fisher). Brilliant II
SyBR Green qPCR Master Mix (Stratagene) was used to conduct RT–
qPCR on the ABI Prism HT7900 Sequence Detection System
(Applied Biosciences). The expression of target genes was normal-
ised to the housekeeping gene HPRT using the formula (2DCt ).
Appendix Table S3 shows the primers used.
Illumina microarray transcriptome analysis
RNA was extracted from MEFs as described above. The Illumina
TotalPrep RNA amplification kit (Ambion) was used to generate
cRNA and whole-genome gene expression analysis performed for
two independent Rnaseh2b/ p53/ MEFs and four Rnaseh2b+/+
p53/ lines using MouseWG-6 v2.0 Expression BeadChips (Illu-
mina). Microarray data were analysed with R 3.1.0, using the
beadarray and Limma v.3.24.15 packages. Raw, non-normalised
bead-summary values were imported from the Illumina BeadStudio
software into R using the beadarray package. The limma function
neqc was used to perform background correction and quantile
normalisation of the raw probe signals. Prior to gene level differen-
tial analysis, probes that were not detected on any arrays were
removed (detection P-value < 0.01), and genes with multiple probes
were replaced with their average. A linear model was applied to the
expression data for each gene. To determine statistically differen-
tially expressed genes, the results of the linear model were
summarised and a Bayes moderated t-test applied. To control for
multiple testing, a Benjamini and Hochberg false discovery rate
value of < 0.05 was used. Gene Ontology enrichment analysis
was performed using the R package clusterProfiler. Genes in
WT MEFs significantly upregulated against Rnaseh2b knockout
(q-value < 0.05 and log2FC > 0) were tested for functional enrich-
ment against the background of genes detected on the array.
Microarray data were deposited at the Gene Expression Omnibus
(GEO)—accession number GSE76942.
siRNA knock-down
MEFs were plated overnight at 2 × 104 cells per well in a 24-well
plate. The following day cells were transfected with short-interfering
RNA (siRNA) oligonucleotides targeting cGAS, STING or designed
against Luciferase, using Dharmafect 1 in Opti-MEM reduced serum
medium (Thermo Fisher Scientific). Appendix Table S4 lists the
oligonucleotide sequences. Transfection medium was replaced with
800 ll complete medium after 6 h, and culture medium was
removed 48 h after transfection and used for ELISA analysis. Total
RNA was extracted from cells as described above. To assess respon-
siveness to poly(I:C) following siRNA treatment, cells were further
transfected with a final concentration of 10 lg/ml of high molecular
weight poly(I:C) (InvivoGen) and culture supernatants assessed
22 h later for CCL5 using ELISA.
CRISPR/Cas9 genome editing
Rnaseh2b/ p53/ MEFs were electroporated using the neon
transfection system (Invitrogen) with vectors based on pSpCas9n
(BB)-2A-GFP, a gift from Feng Zhang (Addgene plasmid # 48140),
expressing two guide RNAs designed against the coding part of exon
1 of murine cGAS/Mb21d1 (NM_173386.5), using previously
described methods (Ran et al, 2013). Rnaseh2b/ p53/ cGAS/
clones were selected by sizing of PCR products of the targeted
region to detect clones in which deletions had occurred; these were
subsequently confirmed by Sanger sequencing ensuring out of frame
deletions in all alleles. Rnaseh2b/ p53/ cGAS+/+ MEF clones
were identified in parallel to act as controls. An additional func-
tional assay was performed to confirm inactivation of cGAS by
assessing cellular responsiveness to transfected dsDNA (1.33 lg/ml
final concentration, ISD naked (InvivoGen)) to ensure the absence
or presence of functional cGAS, and 2030-cGAMP (2 lg/ml final
concentration (InvivoGen)) to confirm the presence of functional
STING. Innate immune activation of Rnaseh2b/ p53/ cGAS+/+
and Rnaseh2b/ p53/ cGAS/ clones was assessed as described
above.
Complementation of RNase H2 null MEFs
The Rnaseh2b/ p53/ MEF line used for complementation was
previously published and was derived from an E10.5 embryo, result-
ing from interbreeding Rnaseh2btm1-hgu-A174T,E202X/+ p53+/ mice
(Reijns et al, 2012). These cells were infected in the presence of
4 lg/ml polybrene with retroviral supernatant from the Phoenix
Ecotropic packaging cell line (Swift et al, 2001) transfected with
pMSCVpuro, allowing expression of EGFP, RNASEH2B (NP_080277)
or RNASEH1 (NP_001273794), and selected for stable integration
with 2 lg/ml puromycin. Phoenix cells and pMSCVpuro were a
kind gift from Dr. Irena Stancheva, University of Edinburgh.
Immunofluorescence
Parental Rnaseh2b/ p53/ MEFs, matching Rnaseh2b+/+
p53/ controls (Reijns et al, 2012) and complemented Rnase-
h2b/ p53/ MEFs (5 × 104 cells per well), were plated on
coverslips in 6-well plates. After 24 h, non-chromatin bound
proteins were extracted using pre-extraction buffer (25 mM HEPES
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pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl2, 0.3 M sucrose,
and 0.5% Triton X-100) for 7 min on ice. Cells were fixed with
4% PFA for 14 min at room temperature (RT). After blocking with
3% FCS in PBS for 30 min at RT, 53BP1 antibody (NB100-904,
Novus Biologicals) was added for 1 h at RT. The next day, Alexa
Fluor 568 goat anti-rabbit secondary antibody (Life technologies)
was applied and incubated for 1 h at RT. Coverslips were mounted
using Vectashield antifade mounting medium with DAPI (Vector
laboratories) and imaged at RT using a Coolsnap HQ CCD camera
(Photometrics) and a Zeiss Axioplan II fluorescence microscope
with Plan-neofluar objectives (×40 and ×63) and acquired with
iVision software (BioVision Technologies). Scoring was done under
blinded conditions.
Statistical analysis
Data were analysed by unpaired t-test for normally distributed quan-
titative data and Mann–Whitney U-tests for nonparametric data as
indicated in the text. One-sample t-tests were employed where para-
metric data were plotted in terms of percentage of control. Prism
(GraphPad Software, Inc) was used throughout.
Expanded View for this article is available online.
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